Applying Updated Findings From SABCS 2023 to HER2+ Breast Cancer Practice
Carey K. Anders, MD, spoke about updated findings in the HER2-positive breast cancer space, based on data from 2023 SABCS.
Amivantamab Is Preferred First-Line Pick in EGFR Exon 20 NSCLC
During a Training Academy focused on first-line treatment use in non–small cell lung cancer, panelists discussed a patient case and how they would treat that patient in the setting.
Preferred Treatment Options for EGFRMutated Exon 20 Insertion+ NSCLC
A recent Training Academy focused on the advancements of treatment for patients with NSCLC EGFR mutations and exon 20 insertions.
